Back

A non-canonical glucose metabolic rewiring enables resistance to cancer targeted therapy

Zhu, L.

2024-12-20 cancer biology
10.1101/2024.12.19.629335 bioRxiv
Show abstract

Targeting glucose metabolism for cancer therapy is a long-lasting pursuit but with disappointing translational success. Revelation of actionable distinctions between the malignancy traits to achieve selectivity is a prerequisite for fulfilling a therapeutic window. We discover a non-canonical glucose transporter GLUT6-facilitated, lactate-independent, glucose metabolic rewiring that selectively enables resistance to targeted therapy in lung cancer. Downstream, GLUT6 facilitated glucose influx and straying to methylglyoxal which dimerized KEAP1 and upregulated NRF2 pathway to confer resistance. Upstream, GLUT6 was transcriptionally upregulated by therapy-induced MAZ activation. Targeting GLUT6 prevented and overcame resistance to EGFR and KRAS inhibitors and the MAZ-GLUT6-NRF2 signaling correlated with clinical therapy response and relapse. Our findings uncover an unrecognized non-genetic, metabolic mechanism for drug resistance and a scenario specifically determined by a distinct glucose metabolic rewiring in cancer. The preferential dependance of the non-canonical, general-homeostasis-less-perturbing transporter GLUT6 implies a promise for resistance overcoming and for glucose metabolism-targeting strategy, two long and urgent quests.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 4%
26.3%
Similar papers in this journal
2
eLife
● 5828 papers in training set
Top 14%
7.8%
Similar papers in this journal
3
Cell Reports
○ 1498 papers in training set
Top 4%
7.2%
Similar papers in this journal
4
Science Advances
● 1243 papers in training set
Top 3%
6.7%
Similar papers in this journal
5
Cancer Research
● 130 papers in training set
Top 0.9%
4.0%
Similar papers in this journal
50% of probability mass above
6
Nature Chemical Biology
○ 119 papers in training set
Top 0.8%
3.2%
7
Cell Chemical Biology
○ 94 papers in training set
Top 0.5%
2.4%
8
Communications Biology
○ 993 papers in training set
Top 11%
2.1%
9
Advanced Science
○ 286 papers in training set
Top 4%
1.9%
10
eBioMedicine
○ 183 papers in training set
Top 3%
1.7%
11
Signal Transduction and Targeted Therapy
○ 30 papers in training set
Top 0.3%
1.7%
12
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 27%
1.7%
13
Cancer Letters
○ 35 papers in training set
Top 0.6%
1.7%
14
Oncogene
○ 85 papers in training set
Top 1%
1.5%
15
Cell Reports Medicine
○ 153 papers in training set
Top 3%
1.5%
16
iScience
○ 1154 papers in training set
Top 21%
1.5%
17
Redox Biology
○ 70 papers in training set
Top 0.8%
1.4%
18
Cancer Discovery
● 66 papers in training set
Top 1%
1.3%
19
Journal of Clinical Investigation
● 179 papers in training set
Top 4%
1.1%
20
Nature Cancer
○ 39 papers in training set
Top 1%
1.1%
21
Theranostics
● 37 papers in training set
Top 0.8%
1.1%
22
Cell Metabolism
○ 57 papers in training set
Top 1%
0.9%
23
Gastroenterology
○ 42 papers in training set
Top 0.9%
0.9%
24
Nature Metabolism
○ 69 papers in training set
Top 2%
0.8%
25
EMBO Molecular Medicine
○ 95 papers in training set
Top 3%
0.8%
26
Cancer Cell
○ 42 papers in training set
Top 1%
0.8%
27
British Journal of Cancer
○ 49 papers in training set
Top 1%
0.8%
28
Molecular Cancer
○ 16 papers in training set
Top 0.5%
0.6%
29
Cell Discovery
○ 57 papers in training set
Top 1%
0.6%
30
Cell Research
○ 51 papers in training set
Top 2%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.